{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:20:31Z","timestamp":1783124431786,"version":"3.54.6"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology","doi-asserted-by":"publisher","award":["BT\/MED\/30\/SP11239\/2015"],"award-info":[{"award-number":["BT\/MED\/30\/SP11239\/2015"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Polypyrimidine tract binding protein 2 (PTBP2) regulates alternative splicing in neuronal, muscle, and Sertoli cells. PTBP2 and its paralog, PTBP1, which plays a role in B-cell development, was found to be expressed aberrantly in myeloid leukemia. Genetic ablation of Ptbp2 in the cells resulted in decreased cellular proliferation and repopulating ability, decreased reactive oxygen species (ROS), and altered mitochondrial morphology. RNA immunoprecipitation followed by sequencing (RIP-seq) and functional assays confirmed that PTBP2 binds to Bcl-2 Interacting Protein 3 (Bnip3)-3\u2019UTR and stabilizes its expression. Our study also suggests that PTBP2 promotes autophagy, as evidenced by the low levels of LC3-II expression in Ptbp2-knockout cells treated with Bafilomycin A1. This effect was restored upon overexpression of Bnip3 in the knockout cells. Notably, when KCL22-NTC cells were subcutaneously injected into the flanks of mice, they gave rise to malignant tumors, unlike Ptbp2-KO-KCL22 cells. Also, transplantation of KCL22 cells through the tail vein in NOD\/SCID mice resulted in higher cell engraftment and increased infiltration of malignant cells in the extramedullary organs. Our study underscores the role of PTBP2 in promoting cell proliferation and tumor formation while enhancing autophagy through Bnip3, thereby supporting the role of PTBP2 as an oncogene in CML.<\/jats:p>","DOI":"10.1038\/s41419-025-07529-9","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T17:32:34Z","timestamp":1742491954000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["PTBP2 promotes cell survival and autophagy in chronic myeloid leukemia by stabilizing BNIP3"],"prefix":"10.1038","volume":"16","author":[{"given":"Bibhudev","family":"Barik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shristi","family":"Lama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajitha","family":"IS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayantan","family":"Chanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Mohapatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sutapa","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghanashyam","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5730-4705","authenticated-orcid":false,"given":"Soumen","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"7529_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100825","volume":"49","author":"AEG Osman","year":"2021","unstructured":"Osman AEG, Deininger MW. Chronic myeloid leukemia: modern therapies, current challenges and future directions. Blood Rev. 2021;49:100825.","journal-title":"Blood Rev"},{"key":"7529_CR2","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1002\/cncr.30864","volume":"123","author":"P Jain","year":"2017","unstructured":"Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour EJ, Nogueras Gonzalez G, et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients. Cancer. 2017;123:4391\u2013402.","journal-title":"Cancer"},{"key":"7529_CR3","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/nrc2147","volume":"7","author":"JV Melo","year":"2007","unstructured":"Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7:441\u201353.","journal-title":"Nat Rev Cancer"},{"issue":"Suppl 1","key":"7529_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3109\/10428194.2010.546920","volume":"52","author":"JM Diamond","year":"2011","unstructured":"Diamond JM, Melo JV. Mechanisms of resistance to BCR-ABL kinase inhibitors. Leuk Lymphoma. 2011;52(Suppl 1):12\u201322.","journal-title":"Leuk Lymphoma"},{"key":"7529_CR5","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1038\/leu.2016.51","volume":"30","author":"M Wagle","year":"2016","unstructured":"Wagle M, Eiring AM, Wongchenko M, Lu S, Guan Y, Wang Y, et al. A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Leukemia. 2016;30:1493\u2013501.","journal-title":"Leukemia"},{"key":"7529_CR6","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1042\/BST0360641","volume":"36","author":"K Sawicka","year":"2008","unstructured":"Sawicka K, Bushell M, Spriggs KA, Willis AE. Polypyrimidine-tract-binding protein: a multifunctional RNA-binding protein. Biochem Soc Trans. 2008;36:641\u20137.","journal-title":"Biochem Soc Trans"},{"key":"7529_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2350-15-80","volume":"15","author":"Z Yang","year":"2014","unstructured":"Yang Z, Chen Y, Fu Y, Yang Y, Zhang Y, Chen Y, et al. Meta-analysis of differentially expressed genes in osteosarcoma based on gene expression data. BMC Med Genet. 2014;15:80.","journal-title":"BMC Med Genet"},{"key":"7529_CR8","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/bjc.2014.383","volume":"111","author":"Q Ji","year":"2014","unstructured":"Ji Q, Zhang L, Liu X, Zhou L, Wang W, Han Z, et al. Long non-coding RNA MALAT1 promotes tumour growth and metastasis in colorectal cancer through binding to SFPQ and releasing oncogene PTBP2 from SFPQ\/PTBP2 complex. Br J Cancer. 2014;111:736\u201348.","journal-title":"Br J Cancer"},{"key":"7529_CR9","first-page":"3075","volume":"20","author":"J Sun","year":"2019","unstructured":"Sun J, Xu H, Qi M, Zhang C, Shi J. Identification of key genes in osteosarcoma by meta\u2011analysis of gene expression microarray. Mol Med Rep. 2019;20:3075\u201384.","journal-title":"Mol Med Rep"},{"key":"7529_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25892-x","volume":"12","author":"JH Kim","year":"2021","unstructured":"Kim JH, Jeong K, Li J, Murphy JM, Vukadin L, Stone JK, et al. SON drives oncogenic RNA splicing in glioblastoma by regulating PTBP1\/PTBP2 switching and RBFOX2 activity. Nat Commun. 2021;12:5551.","journal-title":"Nat Commun"},{"key":"7529_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/15548627.2016.1222992","volume":"13","author":"LB Frankel","year":"2017","unstructured":"Frankel LB, Lubas M, Lund AH. Emerging connections between RNA and autophagy. Autophagy. 2017;13:3\u201323.","journal-title":"Autophagy"},{"key":"7529_CR12","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.tibs.2020.07.007","volume":"45","author":"MH Abildgaard","year":"2020","unstructured":"Abildgaard MH, Brynjolfsdottir SH, Frankel LB. The autophagy-RNA interplay: degradation and beyond. Trends Biochem Sci. 2020;45:845\u201357.","journal-title":"Trends Biochem Sci"},{"key":"7529_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/path.2697","volume":"221","author":"D Glick","year":"2010","unstructured":"Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. J Pathol. 2010;221:3\u201312.","journal-title":"J Pathol"},{"key":"7529_CR14","doi-asserted-by":"publisher","first-page":"724","DOI":"10.2174\/15680096113139990088","volume":"13","author":"GV Helgason","year":"2013","unstructured":"Helgason GV, Mukhopadhyay A, Karvela M, Salomoni P, Calabretta B, Holyoake TL. Autophagy in chronic myeloid leukaemia: stem cell survival and implication in therapy. Curr Cancer Drug Targets. 2013;13:724\u201334.","journal-title":"Curr Cancer Drug Targets"},{"key":"7529_CR15","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1111\/j.1349-7006.2008.00932.x","volume":"99","author":"Y Mishima","year":"2008","unstructured":"Mishima Y, Terui Y, Mishima Y, Taniyama A, Kuniyoshi R, Takizawa T, et al. Autophagy and autophagic cell death are next targets for elimination of the resistance to tyrosine kinase inhibitors. Cancer Sci. 2008;99:2200\u20138.","journal-title":"Cancer Sci"},{"key":"7529_CR16","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1172\/JCI35660","volume":"119","author":"C Bellodi","year":"2009","unstructured":"Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Investig. 2009;119:1109\u201323.","journal-title":"J Clin Investig"},{"key":"7529_CR17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.biocel.2019.01.018","volume":"109","author":"SR Nandagopalan","year":"2019","unstructured":"Nandagopalan SR, Agatheeswaran S, Vadlamudi Y, Biswas S, Biswas G, Pattnayak NC, et al. PTBP2 exon 10 inclusion is associated with the progression of CML and it is BCR-ABL1 dependent. Int J Biochem Cell Biol. 2019;109:69\u201375.","journal-title":"Int J Biochem Cell Biol"},{"key":"7529_CR18","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1074\/jbc.M112.399345","volume":"288","author":"Y Zhu","year":"2013","unstructured":"Zhu Y, Massen S, Terenzio M, Lang V, Chen-Lindner S, Eils R, et al. Modulation of serines 17 and 24 in the LC3-interacting region of Bnip3 determines pro-survival mitophagy versus apoptosis. J Biol Chem. 2013;288:1099\u2013113.","journal-title":"J Biol Chem"},{"key":"7529_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0204792","volume":"13","author":"A Singh","year":"2018","unstructured":"Singh A, Azad M, Shymko MD, Henson ES, Katyal S, Eisenstat DD, et al. The BH3 only Bcl-2 family member BNIP3 regulates cellular proliferation. PLoS ONE. 2018;13:e0204792.","journal-title":"PLoS ONE"},{"key":"7529_CR20","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1073\/pnas.0510423103","volume":"103","author":"JP Radich","year":"2006","unstructured":"Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA. 2006;103:2794\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7529_CR21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3109\/10715761003667554","volume":"44","author":"GY Liou","year":"2010","unstructured":"Liou GY, Storz P. Reactive oxygen species in cancer. Free Radic Res. 2010;44:479\u201396.","journal-title":"Free Radic Res"},{"key":"7529_CR22","doi-asserted-by":"crossref","unstructured":"Yao CH, Wang R, Wang Y, Kung CP, Weber JD, Patti GJ. Mitochondrial fusion supports increased oxidative phosphorylation during cell proliferation. eLife. 2019;8:e41351.","DOI":"10.7554\/eLife.41351"},{"key":"7529_CR23","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/cdd.2008.185","volume":"16","author":"TR Burton","year":"2009","unstructured":"Burton TR, Gibson SB. The role of Bcl-2 family member BNIP3 in cell death and disease: NIPping at the heels of cell death. Cell Death Differ. 2009;16:515\u201323.","journal-title":"Cell Death Differ"},{"key":"7529_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-1138-4","volume":"19","author":"X Li","year":"2020","unstructured":"Li X, He S, Ma B. Autophagy and autophagy-related proteins in cancer. Mol Cancer. 2020;19:12.","journal-title":"Mol Cancer"},{"key":"7529_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04795-9","volume":"13","author":"K Liu","year":"2022","unstructured":"Liu K, Zhao Q, Sun H, Liu L, Wang C, Li Z, et al. BNIP3 (BCL2 interacting protein 3) regulates pluripotency by modulating mitochondrial homeostasis via mitophagy. Cell Death Dis. 2022;13:334.","journal-title":"Cell Death Dis"},{"key":"7529_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121328","volume":"10","author":"Y Ding","year":"2015","unstructured":"Ding Y, Gao H, Zhao L, Wang X, Zheng M. Mitofusin 2-deficiency suppresses cell proliferation through disturbance of autophagy. PLoS ONE. 2015;10. e0121328.","journal-title":"PLoS ONE"},{"key":"7529_CR27","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1126\/science.1231031","volume":"340","author":"Y Chen","year":"2013","unstructured":"Chen Y, Dorn GW. 2nd. PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria. Science. 2013;340:471\u20135.","journal-title":"Science"},{"key":"7529_CR28","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/nm.2187","volume":"16","author":"MG Kharas","year":"2010","unstructured":"Kharas MG, Lengner CJ, Al-Shahrour F, Bullinger L, Ball B, Zaidi S, et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med. 2010;16:903\u20138.","journal-title":"Nat Med"},{"key":"7529_CR29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.yexcr.2013.09.009","volume":"320","author":"H Zhang","year":"2014","unstructured":"Zhang H, Tan S, Wang J, Chen S, Quan J, Xian J, et al. Musashi2 modulates K562 leukemic cell proliferation and apoptosis involving the MAPK pathway. Exp Cell Res. 2014;320:119\u201327.","journal-title":"Exp Cell Res"},{"key":"7529_CR30","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jare.2020.04.016","volume":"24","author":"SQ Li","year":"2020","unstructured":"Li SQ, Liu J, Zhang J, Wang XL, Chen D, Wang Y, et al. Transcriptome profiling reveals the high incidence of hnRNPA1 exon 8 inclusion in chronic myeloid leukemia. J Adv Res. 2020;24:301\u201310.","journal-title":"J Adv Res"},{"key":"7529_CR31","first-page":"1274","volume":"56","author":"M Wang","year":"2020","unstructured":"Wang M, Sun XY, Zhou YC, Zhang KJ, Lu YZ, Liu J, et al. Suppression of Musashi\u20112 by the small compound largazole exerts inhibitory effects on malignant cells. Int J Oncol. 2020;56:1274\u201383.","journal-title":"Int J Oncol"},{"key":"7529_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.682859","volume":"11","author":"M Liu","year":"2021","unstructured":"Liu M, Yang L, Liu X, Nie Z, Zhang X, Lu Y, et al. HNRNPH1 is a novel regulator of cellular proliferation and disease progression in chronic myeloid leukemia. Front Oncol. 2021;11:682859.","journal-title":"Front Oncol"},{"key":"7529_CR33","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1095\/biolreprod.110.087114","volume":"84","author":"M Xu","year":"2011","unstructured":"Xu M, Hecht NB. Polypyrimidine tract-binding protein 2 binds to selective, intronic messenger RNA and microRNA targets in the mouse testis. Biol Reprod. 2011;84:435\u20139.","journal-title":"Biol Reprod"},{"key":"7529_CR34","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/ni.1977","volume":"12","author":"U Nowak","year":"2011","unstructured":"Nowak U, Matthews AJ, Zheng S, Chaudhuri J. The splicing regulator PTBP2 interacts with the cytidine deaminase AID and promotes binding of AID to switch-region DNA. Nat Immunol. 2011;12:160\u20136.","journal-title":"Nat Immunol"},{"key":"7529_CR35","doi-asserted-by":"publisher","DOI":"10.34133\/research.0033","volume":"6","author":"J Tang","year":"2023","unstructured":"Tang J, He J, Guo H, Lin H, Li M, Yang T, et al. PTBP2-mediated alternative splicing of IRF9 controls tumor-associated monocyte\/macrophage chemotaxis and repolarization in neuroblastoma progression. Research. 2023;6:0033.","journal-title":"Research"},{"key":"7529_CR36","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/brain\/awp153","volume":"132","author":"HC Cheung","year":"2009","unstructured":"Cheung HC, Hai T, Zhu W, Baggerly KA, Tsavachidis S, Krahe R, et al. Splicing factors PTBP1 and PTBP2 promote proliferation and migration of glioma cell lines. Brain. 2009;132:2277\u201388.","journal-title":"Brain"},{"key":"7529_CR37","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1101\/gad.1558107","volume":"21","author":"PL Boutz","year":"2007","unstructured":"Boutz PL, Stoilov P, Li Q, Lin CH, Chawla G, Ostrow K, et al. A post-transcriptional regulatory switch in polypyrimidine tract-binding proteins reprograms alternative splicing in developing neurons. Genes Dev. 2007;21:1636\u201352.","journal-title":"Genes Dev"},{"key":"7529_CR38","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1101\/gad.191338.112","volume":"26","author":"DD Licatalosi","year":"2012","unstructured":"Licatalosi DD, Yano M, Fak JJ, Mele A, Grabinski SE, Zhang C, et al. Ptbp2 represses adult-specific splicing to regulate the generation of neuronal precursors in the embryonic brain. Genes Dev. 2012;26:1626\u201342.","journal-title":"Genes Dev"},{"key":"7529_CR39","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1016\/j.celrep.2017.05.089","volume":"19","author":"MM Hannigan","year":"2017","unstructured":"Hannigan MM, Zagore LL, Licatalosi DD. Ptbp2 controls an alternative splicing network required for cell communication during spermatogenesis. Cell Rep. 2017;19:2598\u2013612.","journal-title":"Cell Rep"},{"key":"7529_CR40","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1080\/15548627.2016.1162359","volume":"12","author":"M Karvela","year":"2016","unstructured":"Karvela M, Baquero P, Kuntz EM, Mukhopadhyay A, Mitchell R, Allan EK, et al. ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells. Autophagy. 2016;12:936\u201348.","journal-title":"Autophagy"},{"key":"7529_CR41","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1182\/blood-2011-01-330621","volume":"118","author":"GV Helgason","year":"2011","unstructured":"Helgason GV, Karvela M, Holyoake TL. Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. Blood. 2011;118:2035\u201343.","journal-title":"Blood"},{"key":"7529_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.923890","volume":"12","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Chen B, Yan J, Zhao W, Dou P, Sun N, et al. BNIP3 upregulation characterizes cancer cell subpopulation with increased fitness and proliferation. Front Oncol. 2022;12:923890.","journal-title":"Front Oncol"},{"key":"7529_CR43","doi-asserted-by":"publisher","first-page":"6280","DOI":"10.1080\/21655979.2022.2036399","volume":"13","author":"G Zhang","year":"2022","unstructured":"Zhang G, Xu Z, Yu M, Gao H. Bcl-2 interacting protein 3 (BNIP3) promotes tumor growth in breast cancer under hypoxic conditions through an autophagy-dependent pathway. Bioengineered. 2022;13:6280\u201392.","journal-title":"Bioengineered"},{"key":"7529_CR44","doi-asserted-by":"crossref","unstructured":"Takai T, Yoshikawa Y, Inamoto T, Minami K, Taniguchi K, Sugito N, et al. A novel combination RNAi toward Warburg effect by replacement with miR-145 and silencing of PTBP1 induces apoptotic cell death in bladder cancer cells. Int J Mol Sci. 2017;18:179.","DOI":"10.3390\/ijms18010179"},{"key":"7529_CR45","doi-asserted-by":"publisher","first-page":"8930","DOI":"10.1002\/jcp.26823","volume":"233","author":"X Wang","year":"2018","unstructured":"Wang X, Li Y, Fan Y, Yu X, Mao X, Jin F. PTBP1 promotes the growth of breast cancer cells through the PTEN\/Akt pathway and autophagy. J Cell Physiol. 2018;233:8930\u20139.","journal-title":"J Cell Physiol"},{"key":"7529_CR46","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/sj.emboj.7601963","volume":"27","author":"G Twig","year":"2008","unstructured":"Twig G, Elorza A, Molina AJ, Mohamed H, Wikstrom JD, Walzer G, et al. Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. EMBO J. 2008;27:433\u201346.","journal-title":"EMBO J"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07529-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07529-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07529-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T21:15:59Z","timestamp":1742591759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07529-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7529"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07529-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.01.26.577177","asserted-by":"object"}]},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"28 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal protocols were approved by the Institute of Life Sciences (ILS\/IAEC-130-AH\/AUG-18) Animal Ethics Committee. The Institutional Human Ethical Committee approved the study (16\/HEC\/12), and peripheral blood samples were collected from patients after obtaining written informed consent. All procedures involving human participants were performed according to the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"195"}}